home / stock / imrx / imrx news

IMRX News and Press, Immuneering Corporation From 11/10/22

Stock Information
Company Name: Immuneering Corporation
Stock Symbol: IMRX
Market: NASDAQ
Website: immuneering.com
Menu
IMRX IMRX Quote IMRX Short IMRX News IMRX Articles IMRX Message Board
Get IMRX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMRX - Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter Shares Promising Preclinical Data on Second Program IMM-6-415 at the 37 th Annual M...
IMRX - Immuneering Announces Participation in November Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that management will...

IMRX - Immuneering Appoints Leah R. Neufeld as Chief People Officer

CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced the appointment of L...

IMRX - Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced it will present data...
IMRX - Immuneering wins FDA nod to study lead asset in solid tumors

The development-stage biotech Immuneering Corporation ( NASDAQ: IMRX ) announced Friday that the FDA greenlighted its Investigational New Drug (IND) application to study IMM-1-104, its lead candidate targeted at advanced RAS mutant solid tumors. Accordingly, the company ex...

IMRX - Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that the U.S. Food ...

IMRX - Immuneering slides on CFO's exit

Immuneering ( NASDAQ: IMRX ) shares fell 3% in pre-market trading on Wednesday after the report stated chief financial officer Biren Amin has joined another company - Pyramid Biosciences. Boston-based, Pyramid Biosciences is a clinical-stage, biotechnology company foc...
IMRX - Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

The shares of development-stage biotech Immuneering Corporation ( NASDAQ: IMRX ) added ~9% in the pre-market trading Friday after the company announced the filing of an Investigational New Drug (IND) seeking FDA clearance to conduct a clinical trial for its lead asset IMM-...

IMRX - Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today ann...

IMRX - Immuneering Announces Participation in September Investor Conferences

CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today anno...
Previous 10 Next 10